EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Hepatic HIF2α Modulates Extra‐Hepatic Disease‐Associated Phenotypes During Metabolic Dysfunction‐Associated Steatotic Liver Disease

Lorenz M W Holzner iD, Rosa M Korpershoek, Youguo Niu, Anna Cochrane iD, Paula M Darwin iD, Julia Babuta, Areesha Nazeer, Cecilia Castro, Alice P Sowton iD, Alice E Knapton iD, Benjamin D Thackray iD, Julian L Griffin und 4 weitere

Comprehensive Physiology · 2026-10 · 16 (5)

DOI: 10.1002/cph4.70283 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Comprehensive Physiology, online erschienen am 09.10.2026. Verfasst von Lorenz M W Holzner und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physiology, Development and Neuroscience University of Cambridge Cambridge UK. Die Arbeit nennt 81 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust, Biotechnology and Biological Sciences Research Council, British Heart Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metabolic dysfunction‐associated steatotic liver disease (MASLD) afflicts more than one‐third of adults globally, contributing significantly to an increased cardiovascular disease risk. Further, patients with severe liver disease experience muscle weakness and fatigue. Hypoxia‐inducible factor 2α (HIF2α) accumulates in the livers of MASLD patients. Here we sought to understand the role of hepatic HIF2α in mediating hepatic and extra‐hepatic features of MASLD. Using an obese mouse model of MASLD, we investigated the impact of hepatocyte‐specific HIF2α deletion (hHIF2α −/− ) on hepatic, cardiac and skeletal muscle metabolism, and cardiac function. Over 28 weeks, mice were exposed to a high‐fat, high‐fructose, high‐cholesterol (GAN) diet, which induced obesity, hepatic steatosis, fibrosis and inflammation. hHIF2α −/− was associated with greater hepatic NADH‐supported mitochondrial respiration, higher sphingomyelin levels and protection against MASLD induced hyperinsulinaemia, but not against hepatic manifestations of MASLD. Instead, in the hearts of GAN‐fed mice, hHIF2α −/− caused diacylglycerol and long‐chain acyl‐carnitine accumulation and exacerbated diet‐induced ceramide accumulation. Langendorff‐perfused hearts from hHIF2α −/− mice showed systolic and diastolic dysfunction, including 24% lower left ventricular developed pressure and 34% lower maximal rate of relaxation (dP/dt min ). However, isolated hearts from hHIF2α −/− mice were protected against MASLD‐associated sympathetic dominance, determined using autonomic receptor agonist stimulation. Both GAN‐feeding and hHIF2α −/− were associated with lower lean mass (14% and 5.4% lower than respective controls), whilst hHIF2α −/− enhanced OXPHOS‐associated protein levels in gastrocnemius muscle. Overall, hHIF2α −/− resulted in detrimental extra‐hepatic effects, including myocardial lipid accumulation, impaired cardiac function, and loss of whole‐body lean mass, thereby worsening the systemic presentation of MASLD‐associated pathological features.

Schlagwörter

Stichwörter der Autor:innen

HIF2αMASLDcardiac dysfunctionhypoxia signalinglipidomicslivermetabolismmitochondria

Autor:innen und Institutionen

  • Department of Physiology, Development and Neuroscience University of Cambridge Cambridge UK.
  • Department of Human Movement Sciences, Faculty of Behavioural and Movement Sciences Vrije Universiteit Amsterdam, Amsterdam Movement Sciences Amsterdam the Netherlands.
  • The Loke Centre for Trophoblast Research University of Cambridge Cambridge UK.
  • The Rowett Institute University of Aberdeen Aberdeen UK.
  • Division of Systems Medicine, Department of Metabolism, Digestion and Reproduction Imperial College London, Hammersmith Hospital Campus London UK.

ORCID-Profile: Lorenz M W Holzner, Anna Cochrane, Paula M Darwin, Alice P Sowton, Alice E Knapton, Benjamin D Thackray, Dino A Giussani, Rob C I Wüst, Andrew J Murray

Förderung

  • Wellcome Trust
  • Biotechnology and Biological Sciences Research Council
  • British Heart Foundation
  • Research Councils UK Centre for Energy Epidemiology
  • Evelyn Trust
  • Medical Research Council

Zitieren

APA

Holzner, L. M. W., Korpershoek, R. M., Niu, Y., Cochrane, A., Darwin, P. M., Babuta, J., Nazeer, A., Castro, C., Sowton, A. P., Knapton, A. E., Thackray, B. D., Griffin, J. L., Hall, Z., Giussani, D. A., Wüst, R. C. I., & Murray, A. J. (2026). Hepatic HIF2α Modulates Extra‐Hepatic Disease‐Associated Phenotypes During Metabolic Dysfunction‐Associated Steatotic Liver Disease. Comprehensive Physiology, 16(5). https://doi.org/10.1002/cph4.70283

Vancouver

Holzner LMW, Korpershoek RM, Niu Y, Cochrane A, Darwin PM, Babuta J, et al. Hepatic HIF2α Modulates Extra‐Hepatic Disease‐Associated Phenotypes During Metabolic Dysfunction‐Associated Steatotic Liver Disease. Comprehensive Physiology. 2026;16(5). doi:10.1002/cph4.70283

BibTeX
@article{Holzner2026,
  author = {Holzner, Lorenz M W and Korpershoek, Rosa M and Niu, Youguo and Cochrane, Anna and Darwin, Paula M and Babuta, Julia and Nazeer, Areesha and Castro, Cecilia and Sowton, Alice P and Knapton, Alice E and Thackray, Benjamin D and Griffin, Julian L and Hall, Zoe and Giussani, Dino A and Wüst, Rob C I and Murray, Andrew J},
  title = {Hepatic HIF2α Modulates Extra‐Hepatic Disease‐Associated Phenotypes During Metabolic Dysfunction‐Associated Steatotic Liver Disease},
  journal = {Comprehensive Physiology},
  year = {2026},
  volume = {16},
  number = {5},
  doi = {10.1002/cph4.70283}
}
Kostenlos starten →